Herpes simplex virus type 1 (HSV-1) is a common human pathogen that establishes life-long latent infection in sensory neurones. This makes it potentially useful as a gene therapy vector to target neuronal cells. HSV-1 enters cells by membrane fusion, the viral envelope and most tegument proteins dissociate, and the capsid is transported to the cell nucleus to establish infection. There is increasing evidence that the retrograde transport of HSV-1 along sensory axons is mediated by cytoplasmic dynein, but the viral and cellular proteins involved are not known. Cytoplasmic dynein is the major molecular motor involved in minus-end-directed cellular transport along microtubules. It is a large complex molecule, with heavy chains providing motility, while intermediate and light chains are involved in specific cargo binding. A library of HSV-1 capsid and tegument structural genes was constructed and tested for interaction with dynein subunits in a yeast two-hybrid system. A strong interaction was demonstrated between the HSV-1 outer capsid protein VP26 (UL35), as well as the tegument protein VP11/12 (UL46), with the homologous 14 kDa dynein light chains rp3 and Tctex1. In vitro pull-down assays confirmed binding of VP26 to rp3, Tctex1 and cytoplasmic dynein complexes. Recombinant HSV-1 capsids +/- VP26 were used in similar pull-down assays. Only VP26+ capsids bound to rp3. Recombinant HSV-1 capsids were microinjected into living cells and incubated at 37�C. After 1 h capsids were observed to co-localise with rp3, Tctex1 and microtubules. After 2 or 4 h VP26+ capsids had moved closer to the cell nucleus, while VP26- capsids remained in a random distribution. Our results suggest that the HSV-1 outer capsid protein VP26 mediates binding of incoming capsids to the retrograde motor cytoplasmic dynein during cellular infection, through interactions with dynein light chains. It is hoped that these findings will help in the development of a synthetic viral vector, which may allow targeted gene therapy in patients with neurological diseases.

Kinesin-1 transports various cargos along the axon, while the light chain subunits play a role in selecting the types of cargos to transport. However, the mechanisms of cargo recognition and interaction have yet to be characterized. Both c-Jun kinase-interacting protein-1 (JIP1) and alcadein-1 (ALC1) are kinesin-1 cargos and compete with each other for the axonal transport machinery. I identified two polar patches of KLC1 that play a role in the interactions with JIP1 and ALC1, respectively. The main components of these two polar patches are asparagine “clamps” surrounded by positively charged lysines. Consistent with this finding, negatively charged residues of JIP1 and ALC1 are required to interact with KLC1. By structural modeling, I narrowed down the possible key residues of KLC1 that are required for interaction with c-Jun kinase interacting protein-3 (JIP3). Together, these findings reveal the versatility of KLC in the mode of interaction with many different cargos.

Kinesin-1 transports various cargos along the axon, while the light chain subunits play a role in selecting the types of cargos to transport. However, the mechanisms of cargo recognition and interaction have yet to be characterized. Both c-Jun kinase-interacting protein-1 (JIP1) and alcadein-1 (ALC1) are kinesin-1 cargos and compete with each other for the axonal transport machinery. I identified two polar patches of KLC1 that play a role in the interactions with JIP1 and ALC1, respectively. The main components of these two polar patches are asparagine “clamps” surrounded by positively charged lysines. Consistent with this finding, negatively charged residues of JIP1 and ALC1 are required to interact with KLC1. By structural modeling, I narrowed down the possible key residues of KLC1 that are required for interaction with c-Jun kinase interacting protein-3 (JIP3). Together, these findings reveal the versatility of KLC in the mode of interaction with many different cargos.

This dissertation presents the development of a multielectrode microcompartment platform for understanding signal transduction in the nervous system. The design and fabrication of the system and the characterization of the system for pharmacological and electrophysiological measurements of cultured neurons is presented in this work. The electrophysiological activity of cultured dorsal root ganglion (DRG) neurons and cortical neurons is shown on the MEA substrate. These recordings were measured and tied to the toxicological effects of the chemotherapeutic drug vincristine on DRGs. Conventional electrophysiological recordings (via a patch micropipette) are made routinely to record action potentials and ion channel activity in neurons. Moreover, Campenot chambers (traditional compartmented culture systems) have been used for the last thirty years to study the selective application of drugs to neurons. Both of these techniques are useful and well established; however they have their limitations. For instance, Campenot chambers cannot be used very well for small processs-producing neurons, since the barriers are difficult to tranverse. Moreover, conventional patch recordings are labor-intensive, especially when more than one microelectrode needs to be positioned. The developed system is composed of a two compartment divider, each compartment capable of housing axons or cell bodies. Underneath the divider, the substrate has 60 electrodes, arranged in several lines to accommodate several different neurite tracks. Neurons can be stimulated and their activity can be recorded in both of the compartments. The neurotoxin and chemotherapeutic drug vincristine was tested in the system on the DRGs. The drug caused length-dependent axonal degeneration in the DRGs when applied locally. Moreover, electrophysiological activity in both compartments showed that only the activity in the axonal compartment was affected, leading us to believe that the mechanism behind the degeneration is localized to the distal axon.

Running title: Climbing fibers in myosin Va mutants

Herpes simplex virus type 1 (HSV-1) is a common human pathogen that establishes life-long latent infection in sensory neurones. This makes it potentially useful as a gene therapy vector to target neuronal cells. HSV-1 enters cells by membrane fusion, the viral envelope and most tegument proteins dissociate, and the capsid is transported to the cell nucleus to establish infection. There is increasing evidence that the retrograde transport of HSV-1 along sensory axons is mediated by cytoplasmic dynein, but the viral and cellular proteins involved are not known. Cytoplasmic dynein is the major molecular motor involved in minus-end-directed cellular transport along microtubules. It is a large complex molecule, with heavy chains providing motility, while intermediate and light chains are involved in specific cargo binding. A library of HSV-1 capsid and tegument structural genes was constructed and tested for interaction with dynein subunits in a yeast two-hybrid system. A strong interaction was demonstrated between the HSV-1 outer capsid protein VP26 (UL35), as well as the tegument protein VP11/12 (UL46), with the homologous 14 kDa dynein light chains rp3 and Tctex1. In vitro pull-down assays confirmed binding of VP26 to rp3, Tctex1 and cytoplasmic dynein complexes. Recombinant HSV-1 capsids +/- VP26 were used in similar pull-down assays. Only VP26+ capsids bound to rp3. Recombinant HSV-1 capsids were microinjected into living cells and incubated at 37�C. After 1 h capsids were observed to co-localise with rp3, Tctex1 and microtubules. After 2 or 4 h VP26+ capsids had moved closer to the cell nucleus, while VP26- capsids remained in a random distribution. Our results suggest that the HSV-1 outer capsid protein VP26 mediates binding of incoming capsids to the retrograde motor cytoplasmic dynein during cellular infection, through interactions with dynein light chains. It is hoped that these findings will help in the development of a synthetic viral vector, which may allow targeted gene therapy in patients with neurological diseases.

Thesis (M.Sc. (Anatomy))--Mahidol University, 1982.

La maladie d’Alzheimer est la maladie neurodégénérative la plus fréquente dans le monde industrialisé. Sur le plan neuropathologique, cette maladie est caractérisée par deux types de lésions :les plaques séniles et les dégénérescences neurofibrillaires. <p>Des observations morphologiques précédentes ont permis de mettre en évidence des anomalies du transport axoplasmique dans les neurones chez les patients atteints de la maladie d’Alzheimer. Les mécanismes menant à cette perturbation du transport axoplasmique ne sont pas encore bien établis. La glycogen synthase kinase-3β (GSK-3β) et la cyclin-dependent kinase 5 (Cdk5) associée à son activateur pathologique p25, sont deux kinases clés dont la dérégulation intervient dans la pathogenèse de la maladie d’Alzheimer (MA). Nous avons émis l'hypothèse que ces kinases pourraient jouer un rôle dans la perturbation du transport axoplasmique dans cette maladie.<p><p>Dans la première partie de notre travail, nous nous sommes intéressés à l’effet de la GSK-3β et de Cdk5/p25 sur la croissance des neurites (un processus dépendant du transport axoplasmique) dans un modèle cellulaire, les PC12 différenciées prétraitées au NGF. <p>La surexpression de GSK-3β et de p25 provoque une importante réduction de la croissance neuritique dans ces cellules. Par western blot, nous avons montré que cette réduction est associée à des modifications post-traductionnelles des protéines impliquées dans la régulation du cytosquelette. Ces modifications sont la phosphorylation de la protéine tau et des neurofilaments et l’acétylation de la tubuline α.<p>Cette étude indique donc que la GSK-3β et la protéine p25 contrôlent négativement la croissance neuritique.<p><p>Dans la deuxième partie de notre travail, afin d’étudier la relation entre ces kinases et le transport axoplasmique, nous avons analysé dans des neurones en culture l’effet d’une augmentation d’activité de la GSK-3β et de Cdk5/p25 sur le transport des mitochondries.<p>Pour étudier le déplacement des mitochondries, les neurones en cultures ont été doublement transfectées avec deux plasmides :un marqueur mitochondrial combiné avec la GSK-3β ou p25. Après transfection, le mouvement des mitochondries a été enregistré grâce à la technique du time-lapse.<p>L’étude de la fréquence de trois comportements (mouvement antérograde, mouvement rétrograde et état stationnaire) nous a indiqué que les mitochondries sont normalement en position immobile pendant 70 % de leur temps. La surexpression de GSK-3β ou de p25 augmente la fréquence de cet état stationnaire et diminue de manière plus importante les mouvements antérogrades que rétrogrades sans affecter la vitesse des mitochondries. L’observation au microscope électronique a permis de démontrer la persistance du réseau de microtubules dans les cellules surexprimant GSK-3β ou p25.<p>Le transport des mitochondries est un processus actif faisant intervenir les moteurs moléculaires (kinésine et dynéine) dont le rôle est le transport d’organelles qui repose sur un réseau intact de microtubules.<p>Cette étude suggère donc que la GSK-3β et p25 contrôlent négativement le transport des mitochondries en agissant au niveau des moteurs moléculaires (kinésine et dynéine) plutôt qu’en détruisant le réseau de microtubules.<p><p>Dans la troisième partie de notre travail, nous nous sommes intéressés à l’expression et à la localisation dans le cortex frontal humain et dans le cortex cérébelleux de deux protéines appartenant aux moteurs moléculaires responsables des transports axoplasmiques antérograde et rétrograde :la chaîne légère de la kinésine (KLC1) et la chaîne intermédiaire de la dynéine (DIC). <p>Nous avons observé une diminution du niveau d’expression de la KLC1 et de la DIC dans le cortex frontal (une zone atteinte dans la MA) mais pas dans le cortex cérébelleux chez les patients atteints de la maladie d’Alzheimer par rapport à des sujets contrôles. Une diminution du niveau d’expression de la tubuline-β3 et de la synaptophysine -deux marqueurs neuronaux- a aussi été observée dans le cortex frontal mais pas dans le cortex cérébelleux. Nous avons aussi démontré une hausse de l’état de phosphorylation de la KLC1 dans un modèle cellulaire surexprimant la GSK-3β. Dans le cortex frontal dans la MA, nous avons observé une augmentation de la forme active de la GSK-3β, et une hausse de la phosphorylation de la KLC1. Cette phosphorylation accrue de la KLC1 diminue son activité de transport des organelles.<p>Ces anomalies de l’expression et de la phosphorylation des moteurs moléculaires pourraient jouer un rôle dans les perturbations des transports axoplasmiques dans la MA.<p> / Doctorat en Sciences biomédicales et pharmaceutiques / info:eu-repo/semantics/nonPublished

L'Atrophie Musculaire spinale (SMA) est une maladie neurodégénérative causée par des mutations du gène SMN1 et caractérisée par la dégénérescence sélective des motoneurones alpha de la moelle épinière. les mécanismes moléculaires de la SMA ne sont aps clairs. cependant, deux hypothèses ont été retenues:D'une part, que la déficience en SMN entraine une perturbation de la biogenèse des snRNPs spliceosomales individuelles et par conséquent des défauts d'épissage. pendant ma thèse, nous avons montré que la déficience en SMN provoquait une diminution des particules tri-snRNPs majeures amis surtout mineures et que cela avait des conséquences sur l'épissage d'un sous-groupe de pré-ARNm contenant des introns mineurs.D'autre part, que la déficience en SMN entraine des altérations de transport d'ARN dans les axones, essentiels pour la survie des motoneurones. A part l'ARNm de la beta-actine et l'ARNm de cpg15 récemment identifié, ceux qui pourraient être transportés par SMN n'ont pas été décrits. nous avons donc identifié les ARN interagissant avec les isoformes a-SMN et SMN-fl dans des cellules neuronales, et montré que certains de ces ARN cibles colocalisent avec SMN dans les axones, suggérant qu'elle est impliquée dans leur transport. / Spinal Muscular Atrophy is a neurodegenerative disease caused by mutations in SMN1 gene. SMA is characterized by the loss of alpha-motoneurons of the spinal cord. However, the precise molecular mechanisms underlying the disease are still unkown. two hypotheses have been retained to explain SMA pathigenesis:In one hand, the fact that SMN deficiency leads to a perturbation of individual snRNPs biogenesis and consequently splicing defects. During my PhD, we have shown that SMN deficiency alters the levels of major, but mostly, minor tri-snRNPs. And that leads to splicing defects of a subset of pre-mRNA containing minor introns.In the other hand, that SMN deficiency causes alteration of axonal transport of RNAs crucial to motoneurons survival. Except beta-actin mRNA and the recently identified cpg mRNA, the RNA targets of SMN have not been described. We succeed to identify RNA targets of both a-SMN and SMN-fl isoformes in a neuronal cell line and colocalisation data of some of these targets suggested that SMN could be implicated in the transport of these RNAs.

No description available.